Interview with Rob Bootle: Advancements in Nanopharm’s OINDPs
![](https://nanopharm.co.uk/wp-content/uploads/2023/09/ConversationsWithAnAptarPharmaExpert.jpg)
Join Rob Bootle as he explores his journey at Nanopharm, highlighting the company’s cutting-edge research and development in orally inhaled and nasal drug products (OINDPs).
Cyclosporine A micellar nasal spray characterization and antiviral action against SARS-CoV-2
![](https://nanopharm.co.uk/wp-content/uploads/2023/09/AptarPharmaScientificPublications_Icon.jpg)
Nasal spray innovation with micellar delivery of Cyclosporine A holds promise in combating SARS-CoV-2 infections
Intranasal Drug Delivery: Unravelling the Nanoparticle Formulation Puzzle
![](https://nanopharm.co.uk/wp-content/uploads/2023/09/AptarPharmaScientificPublications_Icon.jpg)
Navigate the complexities of formulating nanoparticles for intranasal drug delivery with expert insights
Dual Excipient Integration in Dry Powder Inhaler Products
![](https://nanopharm.co.uk/wp-content/uploads/2023/09/AptarPharmaScientificPublications_Icon.jpg)
Nanopharm explore the effect of dual excipients on DPI products, boosting performance and shaping formulation in the dry powder inhaler landscape.
Propellant Aerosols & Transition to Low GWP pMDIs
![](https://nanopharm.co.uk/wp-content/uploads/2023/09/AptarPharmaScientificPublications_Icon.jpg)
Understand how the properties of propellant aerosols guide the transition to low global warming potential pMDIs.
Primary Crystallization’s Influence on Fluticasone DPIs
![](https://nanopharm.co.uk/wp-content/uploads/2023/09/AptarPharmaScientificPublications_Icon.jpg)
Discover the impact of crystallization on mechanical properties & secondary processing of Fluticasone Propionate in dry powder inhaler formulations.
Albuterol & Low GWP Propellants: Deposition Prediction
![](https://nanopharm.co.uk/wp-content/uploads/2023/09/AptarPharmaScientificPublications_Icon.jpg)
Explore predictions of regional deposition and systemic exposure of Albuterol Sulfate with low global warming potential propellants in pMDIs.
Raman Spectroscopy for Nasal Suspension Drugs
![](https://nanopharm.co.uk/wp-content/uploads/2023/09/AptarPharmaScientificPublications_Icon.jpg)
Explore a systematic approach in developing Morphologically-Directed Raman Spectroscopy for characterizing nasal suspension drug products.
Assessing Particle Size in DPIs with Spraytec & Unidose
![](https://nanopharm.co.uk/wp-content/uploads/2023/09/AptarPharmaScientificPublications_Icon.jpg)
Assess setups to combine Spraytec & Unidose™ for evaluating particle size distribution in dry powder inhalers.
Simulation in In Vitro Bioequivalence for Particle Sizes
![](https://nanopharm.co.uk/wp-content/uploads/2023/09/AptarPharmaScientificPublications_Icon.jpg)
Explore Simulation-informed design in in-vitro bioequivalence trials for particle size distributions’ performance.